Post from Truth Social

A press release with a threat stapled to the end

The post takes Bayer's October 2 announcement and turns it into a personal win on the evening he says he is flying to Ohio. Most of the body is a compressed corporate release: a dollar figure, a location ("near Columbus"), and job categories in a tidy list ("Advanced Manufacturing, Scientific Research, Construction, and more"). Trump's own contribution is the frame around it: "HUGE NEWS FOR OHIO" at the top, "thanks to my strong Pharmaceutical Tariffs" in the middle, and the all-caps ultimatum "BUILD IN AMERICA, HIRE AMERICAN WORKERS, AND PRICE DRUGS FOR AMERICAN PATIENTS FAIRLY — OR PAY" before the sign-off "I LOVE OHIO!"

Who wrote it

The timestamp falls at 6:20 PM Eastern, early evening on a travel day. The style points to staff. The post is grammatical throughout. It carries a parenthetical acronym, "(MFN)", that a casual writer rarely bothers with, uses the press-release noun "Onshoring", and reproduces the release's own "2.2 Billion Dollar" figure and "Pharmaceutical Manufacturing Campus" wording. The Tom Cotton posts from the same day look different. They have the doubled "by by 34 points," a digression about people "forgetting to do so" when changing clocks, and a winning margin that grows from "34 points" to "almost 40 points" across two consecutive posts. Those read as Trump's own typing or dictation. Here the first-person "where I am heading right now" and the "I LOVE OHIO!" coda are the parts most likely his, or written to sound like him.

Claiming the plant

The psychological work here is attribution. Bayer's release presents the New Albany site as part of its U.S. expansion and its pipeline in oncology, cardiovascular and renal care. The post credits it to "my strong Pharmaceutical Tariffs." This is rationalization in a mild, everyday form: an outcome with several causes gets assigned to the one cause that belongs to the speaker. The motive profile is agentic (achievement striving, assertiveness, status through credit) with thin communal content. Ohioans appear as recipients of "thousands of Jobs," and the closing affection ("I LOVE OHIO!") is directed at a rally audience he is about to meet.

The last line switches from celebration to threat. "OR PAY" is aimed at "Companies everywhere" and names no firm. It works as a policy warning in the tariff idiom he has used since his first term. This is the dealmaker protagonist: reward for compliance, cost for refusal. The narrative is a small redemption sequence, in which manufacturing that left comes back because of his intervention. No contrasting other is named.

There is no injury in view and no rage. The trigger is a favorable news item he can claim before an appearance in the state, which makes this a grandiose maintenance post. The absence of any enemy is the clearest contrast with the same afternoon's Cotton posts, where a Republican senator is pressured in public with "unlike Tom, I won that Great State." Splitting, devaluation and paranoid content all depend on an adversary, and this post has none. The language is fluent and sequential, but because the text is most likely staff-drafted, it says little about his cognition.

The numbers

The announcement is real and the location is right: New Albany is a Columbus suburb. "Thousands of Jobs" stretches the release, which projects about 600 permanent positions and roughly 1,500 construction jobs, with production modules not operating until 2031 and 2034. The "600 BILLION DOLLARS" figure is a running total of company pledges, and pledges are not completed investment. "Lower (MFN) Drug Prices" points to the most-favored-nation agreements, whose price effects have so far been concentrated in Medicaid and direct-purchase cash prices, not in prices across the market.

Fact Verification

Bloomberg's October 2, 2026 report (headline: "Bayer to Invest $2.2 Billion in Ohio Drug Plant After US Tariffs Take Effect") says Bayer expects to keep paying the new US drug import tariffs, which the EU-US trade deal caps at 15%. It also reports that Bayer says the factory decision was made without regard to the levies. Reuters asked Sebastian Guth, Bayer's COO and head of US operations, whether the tariffs swayed the decision. He answered: "It's a long-term decision and one that consistently implements our strategy."

Bayer's stated reasons are about the market and the site, not trade policy:

• Guth called it "a very deliberate decision to strengthen our presence in the United States." He noted the pharma division has grown the US share of its global revenue from 20% in 2018 to 35%, and aims to double US sales by the end of the decade.
• Local coverage (Richland Source, ABC6) says Bayer, Gov. DeWine and JobsOhio credited Ohio's workforce, infrastructure and the Ohio Life Science Training Center. JobsOhio contributes $30M to that center. None of these accounts mention tariffs.

Three facts weaken the tariff story further:

• The plant does not help Bayer avoid tariffs for years. The first module opens in 2031 and the second in 2034, so imported Kerendia (made in Germany) and Nubeqa (made in Finland) will keep paying the duty in the meantime.
• Bayer was not among the 26 companies with MFN pricing and tariff-relief deals. That list is the original 17 from late 2025 plus nine more announced August 31, 2026: Alcon, Astellas, BeOne, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva and UCB. Reuters had reported on August 31 that Bayer was expected to sign, but it is not on the published list.
• In May 2025 CEO Bill Anderson said the tariff threat was manageable and that Bayer had no plans to change its global manufacturing footprint, describing a "rough balance" between US and European production.

There is a case for some indirect influence. Bloomberg frames the plant as "the latest in a series of investment pledges by European pharmaceutical companies that have been under pressure from the Trump administration" to lower prices and build in the US. The timing (days after the tariffs took effect) and a Commerce Department undersecretary at the announcement fit that backdrop.

Verdict: tariff and pricing pressure is plausible background. But the only direct evidence, Bayer's own statements, contradicts the claim that the investment is "thanks to" the tariffs. The company points to a long-planned strategy of growing in the US market. | | "Pharmaceutical tariffs have led to over $600 billion in new pharma investments" | Half True | The headline number matches the administration's own tally of announced pledges, and at least one independent count. Two parts of the claim go further than the evidence: calling the money "new investments," and crediting it all to tariffs.

How the figure was reached. At the August 31, 2026 White House event announcing nine more MFN deals, officials gave three different totals without reconciling them:

• Commerce Secretary Lutnick said that day's $19.6B took the total to "$638 billion."
• Trump said $640B.
• HHS Secretary Kennedy said $668B.

So "over 600 billion" matches the administration's count.

Other tallies are lower or more qualified:

• The White House's own April 2026 Section 232 fact sheet said the coming tariffs had spurred "approximately $400 billion" in commitments.
• Reuters' August 2026 factbox put announced US pharma investment at roughly $500B. PhRMA also cites about $500B.
• Think Global Health (November 2025) counted more than $480B, spread over 4 to 10 years.
• A CBRE analysis (February 2026) counted about $600B in multi-year commitments announced in 2025.

"New investments" overstates what has happened:

• These are announced pledges, not money spent. Many run a decade (AbbVie's $100B is over ten years) and include R&D, not just manufacturing.
• CBRE found that only about $60B of the roughly $600B came with specific amounts and locations. It estimated that only about half was genuinely new, with the rest previously planned or already completed projects.
• CBS News found Trump-era totals included money announced before he took office. For example, J&J's $55B includes a $2B project announced in October 2023.
• Think Global Health found little sign that construction had started at scale, and raised the concern that some expansion "could have happened anyway."

"Led to" by tariffs is only partly supported:

• Many pledges came bundled with MFN pricing deals that traded tariff relief for price cuts and investment. The administration's August fact sheet credits those deals, not the tariffs.
• Trump himself said at the August event that "one of the reasons is tariffs," not the only reason.
• Company-level explanations vary. Bayer, the subject of this post, says its plant is unrelated to the tariffs.

Verdict: the dollar figure is real as a count of announced pledges, and tariff threats clearly played some part in the wave of announcements. But calling it "over $600 billion in new pharma investments" caused by tariffs overstates how much is new, how much is concrete, and how much the tariffs alone caused. | | "Tariffs have produced lower (MFN) drug prices" | Half True | Most-favored-nation agreements with several manufacturers cut some prices, mainly in Medicaid and direct-to-consumer cash channels. A broad drop in prices that patients pay has not been shown, and the agreements were linked to tariff relief rather than caused by tariffs alone. |

Overall Veracity: 54%